Get the Stockscreener App
0.3801
8.50%
-0.0353
After Hours:
.37
-0.0101
-2.66%
Gossamer Bio Inc stock is traded at $0.3801, with a volume of 73.45M.
It is down -8.50% in the last 24 hours and down -85.92% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
See More
Previous Close:
$0.4154
Open:
$0.4006
24h Volume:
73.45M
Relative Volume:
6.83
Market Cap:
$87.98M
Revenue:
-
Net Income/Loss:
$-179.82M
P/E Ratio:
-0.2858
EPS:
-1.33
Net Cash Flow:
$-159.16M
1W Performance:
-82.48%
1M Performance:
-85.92%
6M Performance:
-83.89%
1Y Performance:
-69.83%
1-Day Range:
$0.3312
$0.4006
1-Week Range:
$0.3312
$2.2263
52-Week Range:
$0.3312
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.3801 | 96.15M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-10-25 | Upgrade | UBS | Neutral → Buy |
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension - Finviz
Quarterly Trades: Should I set a stop loss on Gossamer Bio IncJuly 2025 Trends & Technical Pattern Based Signals - baoquankhu1.vn
Barclays downgrades Gossamer Bio (GOSS) - MSN
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Re - GuruFocus
Gossamer Bio stock downgraded by Wedbush on trial results - Investing.com South Africa
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Reduction | GOSS Stock News - GuruFocus
These Analysts Slash Their Forecasts On Gossamer Bio - Benzinga
GOSS: Analyst Downgrades and Price Target Slashes by Leerink Par - GuruFocus
GOSS Sees Significant Downgrade as Barclays Lowers Price Target - GuruFocus
This Novo Nordisk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Barclays cuts Gossamer Bio stock rating on trial results By Investing.com - Investing.com Australia
Leerink Downgrades Gossamer Bio to Market Perform From Outperform, Adjusts Price Target to $1 From $6 - marketscreener.com
Leerink cuts Gossamer Bio stock rating on trial miss - Investing.com Australia
Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story - TechStock²
Barclays cuts Gossamer Bio stock rating on trial results - Investing.com
Gossamer Bio’s seralutinib misses primary endpoint in PAH trial By Investing.com - Investing.com India
Leerink cuts Gossamer Bio stock rating on trial miss By Investing.com - Investing.com Canada
GOSS: Gossamer Bio's Phase 3 Study of Seralutinib Shows Promise in PAH - GuruFocus
Gossamer Bio stock plummeted 82% today — what’s behind the crash? - MSN
Gossamer Bio’s seralutinib misses primary endpoint in PAH trial - Investing.com Australia
Gossamer Bio’s Phase 3 PROSERA PAH Trial Misses Primary Endpoint Despite Numerical 6MWD Gain - Yahoo Finance
BREAKING: Gossamer Bio Investors Should Contact Block & - GlobeNewswire
Gossamer slides on phase III readout of seralutinib in PAH - bioworld.com
Gossamer Bio (GOSS) Faces Setback in Phase 3 Trial Results - GuruFocus
Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study - AOL.com
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Asianet Newsable
Gossamer Bio Shareholders Are Encouraged to Contact Johnson - GlobeNewswire
GOSS Faces Setback with Phase 3 PROSERA Results in Pulmonary Hyp - GuruFocus
Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks - Benzinga
Gossamer Bio Reveals Mixed Phase 3 Seralutinib Results - TipRanks
Gossamer Bio Reports Phase 3 Trial of Seralutinib Missed Primary Endpoint - marketscreener.com
Gossamer Bio stock tumbles 80% on trial miss By Investing.com - Investing.com Canada
Gossamer Bio Inc. (Ticker: GOSS) recently disclosed the topline data from its Phase III clinical trial, the Prosera study. - Bitget
Gossamer Bio reports PROSERA topline: missed primary 6MWD endpoint but secondary endpoints and high-risk subgroup favored seralutinib - TradingView
Gossamer Bio shares plummet as lung disease drug fails late-stage trial - Reuters
Gossamer Bio's experimental lung condition drug fails in late-stage trial - TradingView
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - The Joplin Globe
Monaco Asset Management SAM Sells 2,170,584 Shares of Gossamer Bio, Inc. $GOSS - MarketBeat
How Gossamer Bio Inc. stock reacts to Fed rate cuts2025 Trading Recap & Weekly Stock Breakout Alerts - mfd.ru
Street Watch: What is FATEs P E ratio telling usJuly 2025 Selloffs & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Gossamer Bio (NASDAQ:GOSS): The High-Stakes Gamble Drawing Big Bank Interest - AOL.com
Gossamer Bio Target of Unusually High Options Trading (NASDAQ:GOSS) - MarketBeat
A Big Test For SeralutinibWill Gossamer's PAH Data Win Investors' Hearts This Month? - RTTNews
A Look At Gossamer Bio (GOSS) Valuation After Barclays Strong Buy Upgrade And Rising Institutional Ownership - Yahoo Finance
Gossamer Bio’s Stock Whipsaws As Biotech Investors Weigh Risk, Cash Runway And Pipeline Hopes - AD HOC NEWS
Brokers Offer Predictions for Gossamer Bio FY2030 Earnings - MarketBeat
Big Money Bets On Gossamer Bio (GOSS) As Institutional Ownership Hits 81 Percent - AOL.com
Is Gossamer Bio Inc. forming a breakout patternJuly 2025 News Drivers & AI Powered Trade Plan Recommendations - mfd.ru
MB Generational Wealth LLC Buys Shares of 1,414,824 Gossamer Bio, Inc. $GOSS - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Gossamer Bio (NASDAQ:GOSS) Trading Down 4.7%Here's What Happened - MarketBeat
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):